These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 35308307)

  • 1. Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients.
    Wang Y; Chen Y; Zhou X
    Can J Infect Dis Med Microbiol; 2022; 2022():6375870. PubMed ID: 35308307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab treatment in COVID-19: A single center experience.
    Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
    J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6.
    Li P; Lu Z; Li Q; Wang Z; Guo Y; Cai C; Wang S; Liu P; Su X; Huang Y; Dong Y; Qiu W; Ling Y; Yarmus L; Luo F; Zeng L; Bai C; Zhang W
    Front Mol Biosci; 2021; 8():651662. PubMed ID: 33937333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.
    Saffo Z; Guo W; Springer K; Maksimowicz-McKinnon K; Kak V; McKinnon JE; Bhargava P
    J Osteopath Med; 2021 Jul; 121(8):705-714. PubMed ID: 34237804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients.
    Bhandari S; Rankawat G; Singh A
    Indian J Crit Care Med; 2021 Mar; 25(3):260-266. PubMed ID: 33790504
    [No Abstract]   [Full Text] [Related]  

  • 6. Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan.
    Hassan M; Syed F; Zafar M; Iqbal M; Khan NU; Mushtaq HF; Badshah M
    Cureus; 2021 Dec; 13(12):e20219. PubMed ID: 35004038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study.
    Hafez W; Ziade MA; Arya A; Saleh H; Abdelshakor M; Fadl Alla O; Agrawal P; Ali S; Rao SR; Gupta S; Abdelli I; Sebastian H; Ali M; Gador M; Al Baha Z; Abdelrahman A
    Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience of tocilizumab treatment among a cohort of patients with COVID-19 infection from Western India.
    Surana PD; Nayak R; Sheikh A; Haldankar P; Kale J
    J Family Med Prim Care; 2022 Jan; 11(1):123-132. PubMed ID: 35309657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment With Tocilizumab for Patients With COVID-19 Infections: A Case-Series Study.
    Mo Y; Adarkwah O; Zeibeq J; Pinelis E; Orsini J; Gasperino J
    J Clin Pharmacol; 2021 Mar; 61(3):406-411. PubMed ID: 33180360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-center experience of early administration of tocilizumab and corticosteroids in patients with COVID-19 pneumonia.
    Milošević I; Barać A; Jovanović J; Vujović A; Stevanović G; Todorović N; Milošević B
    Trans R Soc Trop Med Hyg; 2023 Sep; 117(9):668-672. PubMed ID: 37103332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
    Potere N; Di Nisio M; Rizzo G; La Vella M; Polilli E; Agostinone A; Spacone A; Di Carlo S; Costantini A; Abbate A; Porreca E; Parruti G
    Int J Infect Dis; 2020 Nov; 100():421-424. PubMed ID: 32768701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia.
    Fomina DS; Lysenko MA; Beloglazova IP; Mutovina ZY; Poteshkina NG; Samsonova IV; Kruglova TS; Chernov AA; Karaulov AV
    Pathog Immun; 2020; 5(1):327-341. PubMed ID: 33089038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab in Combination with Corticosteroids in COVID-19 Pneumonia: A Single-Centre Retrospective Controlled Study.
    Kardos Z; Szabó M; Baráth Z; Miksi Á; Oláh C; Kozma Á; Gergely JA; Csánky E; Szekanecz Z
    Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830885
    [No Abstract]   [Full Text] [Related]  

  • 14. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).
    Colaneri M; Bogliolo L; Valsecchi P; Sacchi P; Zuccaro V; Brandolino F; Montecucco C; Mojoli F; Giusti EM; Bruno R; The Covid Irccs San Matteo Pavia Task Force
    Microorganisms; 2020 May; 8(5):. PubMed ID: 32397399
    [No Abstract]   [Full Text] [Related]  

  • 15. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Tocilizumab in Severely Ill COVID-19 Patients With Rapid Respiratory Deterioration: A Single Center Experience During the Third Pandemic Wave in Greece.
    Rapti V; Livanou ME; Kollias A; Koutouratsas T; Savranakis O; Sakka V; Nitsotolis T; Kakalou E; Athanasiou K; Syrigos KN; Poulakou G
    In Vivo; 2023; 37(3):1312-1317. PubMed ID: 37103076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early tocilizumab treatment was associated with survival benefits in hospitalized kidney transplants with severe COVID-19 infection: A prospective cohort study.
    Tang Y; Yin S; Zhang H; Wu L; Fan Y; Lin T; Song T
    Transpl Immunol; 2024 Dec; 87():102110. PubMed ID: 39218267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appropriate Use of Tocilizumab in COVID-19: Early Use is Beneficial.
    Altunal LN; Aydın M; Özel AS; Çam G
    Infect Dis Clin Microbiol; 2022 Jun; 4(2):116-121. PubMed ID: 38633336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
    Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
    J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia.
    Alex R; Gulam SM; Kumar K
    Adv Virol; 2022; 2022():7060466. PubMed ID: 35721667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.